CervoMed completes enrollment in Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia
CervoMed announced on July 9, 2026 that it has completed enrollment in a Phase 2a study of neflamapimod for the treatment of nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia. The trial enrolled 25 participants receiving oral neflamapimod at doses of 40 mg TID (n=19) or 80 mg BID (n=6) for 24 weeks, followed by a 12-week randomized, double-blind placebo-controlled extension. Interim biomarker data from the study will be presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in November 2026, with first biomarker data expected in early Q4 2026 and first clinical data anticipated in Q1 2027.
- Phase 2a trial of neflamapimod in nfvPPA enrolled 25 participants
- Neflamapimod dosing: 40 mg TID (n=19) or 80 mg BID (n=6) for 24 weeks followed by 12-week randomized, double-blind placebo-controlled extension
- Interim biomarker data to be presented at 19th CTAD Conference, November 16–19, 2026
- First biomarker data anticipated early fourth quarter 2026; first clinical data expected first quarter 2027
- Nature Neuroscience publication demonstrated p38α inhibition reduced axonal transport deficits in transgenic mice harboring tau mutations
- Neflamapimod granted Orphan Drug Designation by U.S. FDA for FTD in 2024
- Estimated 10,000-15,000 people living with nfvPPA in the U.S.; 15,000-20,000 in the E.U.; no approved treatments currently available
Enrollment completion de-risks a clinical program in a rare, untreated neurological condition and positions CervoMed to report biomarker and clinical efficacy data that could support advancement toward a potential registration pathway in nfvPPA, a subset of the broader frontotemporal dementia market.
Derived from 8-K filed 2026-07-09. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →